Fulcrum Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FULC research report →
Companywww.fulcrumtx.com
Fulcrum Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
- CEO
- Alexander C. Sapir
- IPO
- 2019
- Employees
- 45
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $338.74M
- P/E
- -6.27
- P/S
- 0.00
- P/B
- 1.43
- EV/EBITDA
- -3.77
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -27.80%
- ROIC
- -25.50%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-74,880,000 · -669.97%
- EPS
- $-1.18 · -637.50%
- Op Income
- $-84,769,000
- FCF YoY
- -2319.03%
Performance & Tape
- 52W High
- $15.74
- 52W Low
- $5.88
- 50D MA
- $7.36
- 200D MA
- $8.80
- Beta
- 3.01
- Avg Volume
- 1.06M
Get TickerSpark's AI analysis on FULC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 23, 26 | Lehrer-Graiwer Joshua | other | 64,000 |
| Apr 23, 26 | Lehrer-Graiwer Joshua | other | 0 |
| Jan 2, 26 | Gould Robert J | sell | 15,000 |
| Feb 2, 26 | Musso Alan A | other | 170,000 |
| Feb 2, 26 | Oltmans Curtis Gale | other | 170,000 |
| Feb 2, 26 | Gould Robert J | sell | 15,000 |
| Feb 2, 26 | Tourangeau Greg | other | 57,000 |
| Feb 2, 26 | Sapir Alex | other | 650,000 |
| Jan 2, 26 | Gould Robert J | sell | 15,000 |
| Dec 15, 25 | Oltmans Curtis Gale | sell | 3,452 |
Our FULC Coverage
We haven't published any research on FULC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate FULC Report →